A French bioelectronics company “Pixium Vision SA”, based in Paris, has announced the implantation of an artificial retina in a first patient in the UK. … Read More »Pixium SA has announced the first UK patient enrolled in a “PRIMAvera” study with the implantation of a bionic artificial retina
A research study assessing patient and retina specialists’ preferences on the treatment of nAMD has shown a valuable comparison on specific measures. The “relative importance”… Read More »Preferences on neovascular age-related degeneration (nAMD) treatment shows clinicians and patients’ views on options
Researchers at the Universidad de Oviedo, Spain, has reported a systematic review and analysis on stem cell treatments for a range of retinal degenerative disease. … Read More »A systematic review on human stem cell transplantation treatments for retinal degenerative diseases has provided significant promise on the horizon.
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the January 28th, 2022 edition of EURETINA’s web-based digital magazine,… Read More »January 28th, 2021 “EURETINA-Brief”© Issue No. 249
Neurogene Inc. based in Manhattan, New York City, has announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug… Read More »Neurogene Inc. (NYC, USA) has announced to become the first investigative treatment of both neurodegenerative and ocular disease manifestations of Batten Disease.
Dutch researchers at the Radboud University Medical Centre, Nijmegen, and ProQR Therapeutics, a company, based in Leiden, the Netherlands, are enrolling up to 200 patients… Read More »Phase 2/3 anti-sense treatment (”QR-421a”) of retinitis pigmentosa (RP) aims to use exon skipping within the USH2A gene to repair the shortened usherin protein.
Researchers at the Institute of Health Informatics, University College London (UCL), and the International AMD Genomics Consortium (IAMDGC), have reported a significant study on an… Read More »Evidence shows smoking cessation provides a significant reduction on the risk of progressing to age-related macular (AMD) and alcohol consumption having a causal association with geographic atrophy (GA) risk.
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the December 22nd, 2021 edition of EURETINA’s web-based digital magazine,… Read More »December 22nd, 2021 “EURETINA-Brief”© Issue No. 248
In follow up the recent French Competent Authority granting of a Cohort Temporary Authorization for Use (“ATU de Cohorte” or ATUc) in July in 2021,… Read More »GenSight Biologics has reported recent research on how gene therapy transfer works migrating vectors from treated to control eyes.
New longitudinal research in diabetes over a 50-year period in a US study reported that children with type-2 diabetes (T2D) had almost twice the risk… Read More »A 50-year longitudinal study of diabetes on ocular complications in youth-onset type-2 diabetes (T2D) and type 1 diabetes (T1D) suggest different risks on retinopathy